Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, signed a long-term commercial supply agreement for CASGEVY (exagamglogene autotemcel), the first cell therapy based on the CRISPR/Cas9 technology. CASGEVY offers the potential of a one-time treatment for eligible patients with transfusion-dependent beta-thalassemia or sickle cell disease.   Vertex will leverage Lonza’s scientific, regulatory and manufacturing expertise, global manufacturing network,...